peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The analyte molecules in a sample can be partially ordered with respect to the external magnetic field of the spectrometer by manipulating the sample conditions. Common techniques include addition of bacteriophages or bicelles to the sample, or preparation of the sample in a stretched polyacrylamide gel. This creates a local environment that favours certain orientations of nonspherical molecules. Normally in solution NMR the dipolar couplings between nuclei are averaged out because of the fast tumbling of the molecule. The slight overpopulation of one orientation means that a residual dipolar coupling remains to be observed. The dipolar coupling is commonly used in solid state NMR and provides information about the relative orientation of the bond vectors relative to a single global reference frame. Typically the orientation of the N-H vector is probed in an HSQC-like experiment. Initially, residual dipolar couplings were used for refinement of previously determined structures, but attempts at de novo structure determination have also been made.
6 – he won against Oscar Otte, Roman Safiullin, Laslo Đere, Kei Nishikori and Alejandro Davidovich Fokina. In the semifinal, he played Stefanos Tsitsipas, to whom he lost after a 5-set battle. Zverev's first appearance on grass started with a tournament at home in Halle – he lost in the second round to the eventual tournament winner Ugo Humbert. At Wimbledon, seeded No. 4, he equaled his best achievement at the tournament to date – reaching the fourth round for a second time. Along the way he defeated Tallon Griekspoor, Tennys Sandgren and Taylor Fritz. He was defeated in the fourth round by Félix Auger-Aliassime in five sets. Following this run he returned to the top 5 after 2 years on 12 July 2021. At the Olympics, Zverev beat Yen-hsun Lu, Daniel Elahi Galán, Nikoloz Basilashvili and Jérémy Chardy to reach the semifinals. In the semifinals, despite being a set and a break down against world No. 1 Novak Djokovic, Zverev rallied to break back and won eight games in a row on his way to win in three sets. He defeated Karen Khachanov in straight sets in the final to claim the Olympic gold medal. Zverev became the first German man to win a gold medal in singles and the first to win a medal since Tommy Haas won his silver medal at the 2000 Sydney Olympics. Following the Olympics, Zverev reached his second Masters 1000 final of the year at the 2021 Western & Southern Open after defeating Lloyd Harris, Guido Pella, Casper Ruud and Stefanos Tsitsipas after a close three-set battle in the semifinal. Zverev had not won a match at the tournament in six prior appearances.
The most popular weapons of the Cossack cavalrymen were the sabre, or shashka, and the long spear. From the 16th to 19th centuries, Russian Cossacks played a key role in the expansion of the Russian Empire into Siberia (particularly by Yermak Timofeyevich), the Caucasus, and Central Asia. Cossacks also served as guides to most Russian expeditions of civil and military geographers and surveyors, traders, and explorers. In 1648, the Russian Cossack Semyon Dezhnyov discovered a passage between North America and Asia. Cossack units played a role in many wars in the 17th, 18th, and 19th centuries, including the Russo-Turkish Wars, the Russo-Persian Wars, and the annexation of Central Asia. Western Europeans had a lot of contact with Cossacks during the Seven Years' War, and had seen Cossack patrols in Berlin. During Napoleon's Invasion of Russia, Cossacks were the Russian soldiers most feared by the French troops. Napoleon himself stated, "Cossacks are the best light troops among all that exist. If I had them in my army, I would go through all the world with them." Cossacks also took part in the partisan war deep inside French-occupied Russian territory, attacking communications and supply lines. These attacks, carried out by Cossacks along with Russian light cavalry and other units, were one of the first developments of guerrilla warfare tactics and, to some extent, special operations as we know them today. Several thousands of Cossacks were commended by Pyotr Bagration during the French invasion of Russia behind Bug.
Glutathione S-transferase Zeta 1 (also known as maleylacetoacetate isomerase) is an enzyme that in humans is encoded by the GSTZ1 gene on chromosome 14. This gene is a member of the glutathione S-transferase (GSTs) super-family, which encodes multifunctional enzymes important in the detoxification of electrophilic molecules, including carcinogens, mutagens, and several therapeutic drugs, by conjugation with glutathione. This enzyme also plays a significant role in the catabolism of phenylalanine and tyrosine. Thus, defects in this enzyme may lead to severe metabolic disorders, including alkaptonuria, phenylketonuria and tyrosinaemia, and new discoveries may allow the enzyme to protect against certain diseases related to oxidative stress.
Sources: en.wikipedia.org
=== Effect of altering the peptide structure on anti-phalloidin activity === It has been shown that altering any of the proline residues reduces the inhibitory activity to zero. In addition, altering the phenylalanine residues to tyrosine or L-cyclohexylalanine also reduces the activity to zero.
== Mechanism == Myelofibrosis is a clonal neoplastic disorder of hematopoiesis, the formation of blood cellular components. It is one of the myeloproliferative disorders, diseases of the bone marrow in which excess cells are produced at some stage. Production of cytokines such as fibroblast growth factor by the abnormal hematopoietic cell clone (particularly by megakaryocytes) leads to replacement of the hematopoietic tissue of the bone marrow by connective tissue via collagen fibrosis. The decrease in hematopoietic tissue impairs the patient's ability to generate new blood cells, resulting in progressive pancytopenia, a shortage of all blood cell types. However, the proliferation of fibroblasts and deposition of collagen is a secondary phenomenon, and the fibroblasts themselves are not part of the abnormal cell clone. In primary myelofibrosis, progressive scarring, or fibrosis, of the bone marrow occurs, for the reasons outlined above. The result is extramedullary hematopoiesis, i.e. blood cell formation occurring in sites other than the bone marrow, as the hemopoietic cells are forced to migrate to other areas, particularly the liver and spleen. This causes an enlargement of these organs. In the liver, the abnormal size is called hepatomegaly. Enlargement of the spleen is called splenomegaly, which also contributes to causing pancytopenia, particularly thrombocytopenia and anemia. Another complication of extramedullary hematopoiesis is poikilocytosis, or the presence of abnormally shaped red blood cells.
The news reportedly left palaeontologist John Ostrom, who in the 1970s had pioneered the theory that birds evolved from dinosaurs, "in a state of shock." Ostrom later joined an international team of researchers who gathered in Beijing to examine the fossils; other team members included feather expert Alan Brush, fossil bird expert Larry Martin, and Peter Wellnhofer, an expert on the early bird Archaeopteryx. Three specimens have been assigned to Sinosauropteryx prima: the holotype GMV 2123 (and its counter slab [opposite face], NIGP 127586), NIGP 127587, and D 2141. Another specimen, IVPP V14202, was originally assigned to the genus in 2010, but was later designated as the holotype of a separate genus Huadanosaurus. The assignment of an additional larger specimen to S. prima, GMV 2124 (also known as NGMC 2124), was later found to be in error, and most likely belongs to Tyrannosauroidea. All of the fossils were found in the Jianshangou or Dawangzhangzi Beds of the Yixian Formation in the Beipiao and Lingyuan regions of Liaoning, China. These fossil beds have been dated to 124.6–122 million years ago, during the early Aptian stage of the Early Cretaceous.
The known metal ligands are His, Glu, Asp, or Lys and at least one other residue is required for catalysis, which may play an electrophillic role. Of the known metalloproteases, around half contain an HEXXH motif, which has been shown in crystallographic studies to form part of the metal-binding site. The HEXXH motif is relatively common, but can be more stringently defined for metalloproteases as 'abXHEbbHbc', where 'a' is most often valine or threonine and forms part of the S1' subsite in thermolysin and neprilysin, 'b' is an uncharged residue, and 'c' a hydrophobic residue. Proline is never found in this site, possibly because it would break the helical structure adopted by this motif in metalloproteases.
Technetium-99 produces the largest amount of LLFP radioactivity. It emits beta particles of low to medium energy but no gamma rays, so has little hazard on external exposure, but only if ingested. However, technetium's chemistry allows it to form anions (pertechnetate, TcO4−) that are relatively mobile in the environment. Tin-126 has a large decay energy (due to its following short half-life decay product) and is the only LLFP that emits energetic gamma radiation, which is an external exposure hazard. However, this isotope is produced in very small quantities in fission by thermal neutrons, so the energy per unit time from 126Sn is only about 5% as much as from 99Tc for U-235 fission, or 20% as much for 65% U-235+35% Pu-239. Fast fission may produce higher yields. Tin is an inert metal with little mobility in the environment, helping to limit health risks from its radiation. Selenium-79 is produced at low yields and emits only weak radiation. Its decay energy per unit time should be only about 0.2% that of Tc-99. Zirconium-93 is produced at a relatively high yield of about 6%, but its decay is 7.5 times slower than Tc-99, and its decay energy is only 30% as great; therefore its energy production is initially only 4% as great as Tc-99, though this fraction will increase as the Tc-99 decays. 93Zr does produce gamma radiation, but of a very low energy, and zirconium is relatively inert in the environment.
Sources: en.wikipedia.org
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was studied by Pfizer as a potential treatment of metabolic disorders such as type 2 diabetes mellitus. Its development was terminated in 1999.
== External links == Brandt, Marieke (15 November 2017). Tribes and Politics in Yemen: A History of the Houthi Conflict. Oxford University Press. ISBN 9780190911454. "Interview with exiled Houthi". Counterpunch. 3 February 2015. Archived from the original on 18 July 2011. Retrieved 26 March 2015.
=== Light-responsive nanogels === Light-responsive nanogels can be triggered to release their cargo with exposure to light at a certain wavelength. These nanogels are synthesized to contain specific acrylic or coumarin-based bonds that cleave during a photoreaction. With the tunability of the wavelength of light, energy, and time of irradiation, light-responsive nanogels can be triggered to degrade with an increased control over crosslinking density. For example, both the swelling and size of light-responsive nanogels with vinyl groups were found to decrease and produce a sustained release of drugs after irradiation with UV light.
=== Post–Cold War foreign policy uncertainty in the United States === By the early 1990s, the United States had developed a complex global presence but lacked a shared framework for defining post–Cold War threats, interests, and priorities. Policymakers debated whether American leadership should emphasize restraint, engagement, or continued global activism, causing many to criticize the period's self-indulgence, attempts to reorganize the Islamic world, and the failure to integrate the former Soviet Union into NATO. The United States had established a complex global presence by the 1990s and policymakers felt that some structure to explain the "threats, interests and priories" that guide foreign policy was needed, but there was no agreement on how to proceed. Anthony Lake has said that attempts at doctrine-making during this period risked introducing "neo-know-nothing" isolationism or what he termed "irrational" ideas. The goal then of Bush Sr. and Clinton during their terms in office was to develop foreign policy objectives that would support consensus rather than accelerate fragmentation inside America's sphere of influence, ideological confrontation, or rigid doctrine building.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.